FI3054996T3 - Menetelmä erittäin puhtaiden terapeuttisten luulääkeaineiden valmistamiseksi - Google Patents
Menetelmä erittäin puhtaiden terapeuttisten luulääkeaineiden valmistamiseksi Download PDFInfo
- Publication number
- FI3054996T3 FI3054996T3 FIEP14852866.4T FI14852866T FI3054996T3 FI 3054996 T3 FI3054996 T3 FI 3054996T3 FI 14852866 T FI14852866 T FI 14852866T FI 3054996 T3 FI3054996 T3 FI 3054996T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- pharmaceutically acceptable
- chelate composition
- high purity
- dotmp
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 10
- 239000013522 chelant Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/02—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes in nuclear reactors
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
- G21G2001/0094—Other isotopes not provided for in the groups listed above
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- High Energy & Nuclear Physics (AREA)
- Plasma & Fusion (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887603P | 2013-10-07 | 2013-10-07 | |
| PCT/US2014/059385 WO2015054173A1 (en) | 2013-10-07 | 2014-10-07 | High purity therapeutic bone agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3054996T3 true FI3054996T3 (fi) | 2023-08-31 |
Family
ID=52813560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP14852866.4T FI3054996T3 (fi) | 2013-10-07 | 2014-10-07 | Menetelmä erittäin puhtaiden terapeuttisten luulääkeaineiden valmistamiseksi |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10172965B2 (enExample) |
| EP (1) | EP3054996B1 (enExample) |
| JP (2) | JP6787781B2 (enExample) |
| CA (1) | CA2926652C (enExample) |
| DK (1) | DK3054996T3 (enExample) |
| ES (1) | ES2949277T3 (enExample) |
| FI (1) | FI3054996T3 (enExample) |
| HU (1) | HUE062439T2 (enExample) |
| PL (1) | PL3054996T3 (enExample) |
| PT (1) | PT3054996T (enExample) |
| SI (1) | SI3054996T1 (enExample) |
| WO (1) | WO2015054173A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11369700B2 (en) * | 2015-05-25 | 2022-06-28 | IGL Pharma Inc. | DOTMP kit formulations for radioisotopes |
| CA2987242C (en) * | 2015-05-25 | 2023-10-10 | Isotherapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
| CA3052973C (en) * | 2017-02-08 | 2024-02-06 | Igl Pharma, Inc. | Method of use for therapeutic bone agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898724A (en) | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
| US5059412A (en) | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
| US5064633A (en) | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
| US4882142A (en) * | 1988-12-19 | 1989-11-21 | The Dow Chemical Company | Bone marrow suppressing agents |
| MC2260A1 (fr) * | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| WO2000076556A2 (en) * | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| EP1458416A1 (en) * | 2001-12-13 | 2004-09-22 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
| JP2006508939A (ja) * | 2002-10-29 | 2006-03-16 | エンジーン， インコーポレイテッド | 癌処置のための組成物 |
| US20040258614A1 (en) * | 2003-06-20 | 2004-12-23 | University Of Maryland, Baltimore | Microparticles for microarterial imaging and radiotherapy |
| AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| WO2007059195A1 (en) * | 2005-11-14 | 2007-05-24 | University Of Southern California | Integrin-binding small molecules |
| WO2011149844A1 (en) | 2010-05-24 | 2011-12-01 | Iso Therapeutics Group Llc | Delivery of high dose therapeutic radioisotopes to bone |
-
2014
- 2014-10-07 EP EP14852866.4A patent/EP3054996B1/en active Active
- 2014-10-07 SI SI201432033T patent/SI3054996T1/sl unknown
- 2014-10-07 HU HUE14852866A patent/HUE062439T2/hu unknown
- 2014-10-07 FI FIEP14852866.4T patent/FI3054996T3/fi active
- 2014-10-07 CA CA2926652A patent/CA2926652C/en active Active
- 2014-10-07 US US15/027,280 patent/US10172965B2/en active Active
- 2014-10-07 WO PCT/US2014/059385 patent/WO2015054173A1/en not_active Ceased
- 2014-10-07 JP JP2016521278A patent/JP6787781B2/ja active Active
- 2014-10-07 PL PL14852866.4T patent/PL3054996T3/pl unknown
- 2014-10-07 DK DK14852866.4T patent/DK3054996T3/da active
- 2014-10-07 ES ES14852866T patent/ES2949277T3/es active Active
- 2014-10-07 PT PT148528664T patent/PT3054996T/pt unknown
-
2018
- 2018-11-17 US US16/194,324 patent/US10596277B2/en active Active
-
2019
- 2019-03-27 JP JP2019061398A patent/JP7068222B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3054996T3 (pl) | 2023-09-18 |
| ES2949277T3 (es) | 2023-09-27 |
| HUE062439T2 (hu) | 2023-11-28 |
| EP3054996A1 (en) | 2016-08-17 |
| DK3054996T3 (da) | 2023-07-10 |
| US10172965B2 (en) | 2019-01-08 |
| CA2926652C (en) | 2021-07-20 |
| US10596277B2 (en) | 2020-03-24 |
| SI3054996T1 (sl) | 2023-11-30 |
| EP3054996A4 (en) | 2017-07-05 |
| JP2019123731A (ja) | 2019-07-25 |
| US20190083661A1 (en) | 2019-03-21 |
| PT3054996T (pt) | 2023-08-01 |
| EP3054996B1 (en) | 2023-06-21 |
| WO2015054173A1 (en) | 2015-04-16 |
| JP2016532652A (ja) | 2016-10-20 |
| JP6787781B2 (ja) | 2020-11-18 |
| US20160250359A1 (en) | 2016-09-01 |
| CA2926652A1 (en) | 2015-04-16 |
| JP7068222B2 (ja) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107431B (en) | Para-aminohippuric acid (pah) as a renal protective substance | |
| PH12020500515A1 (en) | M-diamide compound and preparation method therefor and use thereof | |
| WO2008059489A3 (en) | Radioimaging applications of and novel formulations of teboroxime | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| PH12014501133A1 (en) | Compositions and methods for treating hepatitis c virus | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| JP2016506935A5 (enExample) | ||
| MX373153B (es) | Derivados de diazacarbazol como ligandos de tau para tomografía por emisión de positrones (pet). | |
| IN2015DN00837A (enExample) | ||
| RU2013155617A (ru) | Композиции для ухода за полостью рта | |
| EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ | |
| JP7068222B2 (ja) | 高純度治療用骨剤 | |
| JP2019123731A5 (enExample) | ||
| JP2025036436A (ja) | 治療用骨剤の使用方法 | |
| Motaleb et al. | Synthesis and evaluation of 99 m Tc-NIDA and 99 m Tc-DMIDA complexes for hepatobiliary imaging | |
| JP2020506239A5 (enExample) | ||
| PH12014501837A1 (en) | Use of modafinil in the treatment of cocaine addicts | |
| WO2002055112A3 (en) | Polypodal chelants for metallopharmaceuticals | |
| RU2009121836A (ru) | Применение соединений три-замещенного глицерина для лечения радиационных поражений | |
| JP2010509294A5 (enExample) | ||
| WO2008054824A3 (en) | Methods for differential detection of hypoxic tissue in a mammalian subject | |
| AR134664A1 (es) | Formulaciones terapéuticas de radioligandos enriquecidas y estables y composiciones farmacéuticas que las comprenden | |
| Bahrami-Samani et al. | Development of 153Sm-bleomycin as a possible therapeutic complex | |
| Rosique et al. | Impact of repeated dose of stable iodine in an in utero rat model using a metabolomic approach |